(e.g., BRAF V600E inhibition with PLX-4032) (Bollag et al., 2010; Serasinghe et al., 2015) . DRP1 is a large cytosolic GTPase that induces fission of the mitochondrial network (Yoon et al., 2001; Smirnova et al., 2001) . For example, when DRP1 is phosphorylated at serine 616 (DRP1 S616℗ ), DRP1 localizes to mitochondria, undergoes oligomerization, and initiates membrane scission (Mishra and Chan, 2014) . DRP1 S616℗ is directly induced by ERK1/2 within the BRAF V600E pathway leading to chronic mitochondrial fission, cancer-associated mitochondrial dysfunction, and resistance to targeted therapies (Serasinghe et al., 2015) . In melanoma, DRP1 S616℗ status dichotomized wild type BRAF (BRAF Wt ) from BRAF V600E disease, suggesting a mechanistic contribution of DRP1 S616℗ in BRAF V600E melanoma (Serasinghe et al., 2015) . Based on these observations, we were interested in determining if DRP1 S616℗ was prevalent in all BRAF V600E skin lesions (e.g., nevi), or if DRP1 S616℗ was indicative of BRAF V600E melanoma. Figure 1d ) were stained. BRAF V600E and DRP1 S616℗ scoring methods were developed (0, 1+ = negative; 2+, 3+ = positive) based on standard histopathological analyses within the Mount Sinai Medical Center and relevant literature (Figures S1a-c) (Pearlstein et al., 2014; Serasinghe et al., 2015) . As control, we examined tissues stained with no primary antibody and rabbit IgG to ensure specificity ; and we also examined total DRP1, which was minimally expressed in normal skin, benign nevi, BRAF Wt melanoma, and BRAF V600E melanoma .
Our benign nevi collection demonstrated no dysplasia at the time of diagnosis, had no known relationship to melanoma, and DRP1 S616℗ was not significantly related to BRAF status (Figures 1a) . While melanoma progression is not absolutely understood, dysplastic nevi are often considered precursors to disease and increase the risk of developing melanoma (Goldstein and Tucker, 2013) . Indeed, analysis of a dysplastic nevi collection from the Mount Sinai Dermatopathology Division which contained a subset of tissues derived from patients eventually diagnosed with melanoma revealed that approximately 79.3% (23/29 cases) of tissues that are DRP1 S616℗ positive are also BRAF V600E , and 92% (23/25 cases) of BRAF V600E dysplastic nevi display DRP1 S616℗ (Figure 1b ). Within the melanoma panel (59 BRAF Wt , 128 BRAF V600E ), we observed DRP1 S616℗ in 91 samples; the vast majority (87/91 cases, 95.6%) was in BRAF V600E tumors ( Figure 1c ). In contrast, only 4 out of 59 BRAF Wt tumors were positive for DRP1 S616℗ . Fisher's Exact (p<0.0001) and Chi-Squared (p<0.0001) analyses revealed that these relationships are highly significant. We also analyzed an additional larger cohort of nevi (containing benign and dysplastic) that are all matched to patients with melanoma, and similar relationships were obtained ( Figure  1d ). Together, these data suggest that DRP1 S616℗ is significantly related to BRAF V600E status in dysplastic nevi and human melanoma, with correlations most striking in BRAF V600E melanoma.
via the pharmacological inhibition of BRAF V600E or MEK (with PLX-4032 or GSK-1120212, respectively) decreased DRP1 S616℗ by western blot and immunofluorescence, but not DRP1 Total , in BRAF V600E melanoma cells (Figures 2a & S4a) . The oncogenic MAPK pathway often reactivates following the inhibition of BRAF V600E or MEK, and this confounds interpreting a direct pro-survival role for DRP1 S616℗ (Holderfield et al., 2014) . Therefore, we examined DRP1 S616℗ contributions in the proliferation and survival of BRAF V600E melanoma cell lines by DRP1 loss of function experiments using RNAi and a small molecule (mDIVI-1) that durably inhibits mitochondrial fission by blocking the DRP1 GTPase (Cassidy-Stone et al., 2008) . A375 cells were infected with RNAi lentivirus against Drp1, and monitored for proliferation. Loss of Drp1 expression correlated with decreased proliferation and clonogenic survival (Figures 2b-e) . Next, A375 cells were treated with mDIVI-1, evaluated by fluorescent microscopy for expected changes to mitochondrial shape (i.e., mitochondrial fusion = DRP1 inhibition), and then scored for apoptotic responses. Indeed, the inhibition of DRP1 function by mDIVI-1 led to a marked decrease in DRP1-dependent mitochondrial fission (Figure 2f ) and dose-dependent apoptosis (Figure 2g ). In contrast, the BRAF Wt melanoma line MeWo displayed minimal DRP1 S616℗ and blunted pro-apoptotic responses to mDIVI-1 treatment ( Figures S5a-b) . We also treated these cells with staurosporine to ensure they had intact pro-apoptotic signaling ( Figure S5c ).
Altogether, these data suggest that the induction of DRP1 S616℗ in dysplastic nevi (and nevi derived from patients eventually diagnosed with melanoma) and primary melanoma is a potential contributing factor to BRAF V600E disease; and examining DRP1 S616℗ status may be a useful progression biomarker along with BRAF V600E to determine which lesions are most likely to develop into disease. DRP1 S616℗ is undetectable in normal skin, and the frequency of genomic alterations to DRP1 is only ∼10% in cancer ( Figures S2a-b & S6a-b) (Cerami et al., 2012; Gao et al., 2013 , Serasinghe et al., 2015 . However, the activation of DRP1 by oncogenic MAPK signaling that occurs during cellular transformation is regulated in the majority of samples (Serasinghe et al., 2015) . In addition, DRP1 S616℗ is markedly enhanced in BRAF V600E positive dysplastic nevi and melanomas. This activation correlates with the survival of BRAF V600E cancer cells following treatment with targeted therapies (Serasinghe et al., 2015) . While there is also a subset of BRAF V600E positive lesions that are negative for DRP1 S616℗ (Figure 1c ), recent studies suggest there are alternative mechanisms to induce mitochondrial hyper-fragmentation and subsequent apoptotic resistance through the mitochondrial dynamics machinery . Collectively, these efforts suggest that studying DRP1, and potentially other proteins involved in orchestrating mitochondrial dynamics and function, may offer a unique perspective to better understand melanoma development, diagnosis, and treatment.
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